Navigation Links
SCOLR Pharma, Inc. First Quarter 2011 Financial Results

BOTHELL, Wash., May 9, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC Bulletin Board: SCLR) today reported financial results for the three months ended March 31, 2011 and also provided updates on a number of key corporate objectives.

Corporate updates include the following:

  • The Company amended its lease with the landlord of the Company's principal office in Bothell, Washington.  The Company and the landlord agreed to reduce the term of the lease so that it will expire on March 31, 2012 rather than January 31, 2016; to reduce the amount of monthly rent and common area maintenance charges from approximately $38,756 to $11,050; and to forgive all past due amounts for unpaid rent and common area maintenance charges.  

  • Stephen J. Turner, President and Chief Executive Officer, and Richard M. Levy, Executive Vice President and Chief Financial Officer, amended their employment agreements to reduce their severance benefits. 

  • Turner said: "Based on anticipated sales of our nutritional products and our reduced expenses we project that our nutritional business will become profitable earlier than previously thought possible. We intend to use any future profits from our nutritional products business to continue development and expansion of that business and to advance our ibuprofen product and pursue licensing or collaborations with pharmaceutical companies and retailers."

    "We are encouraged by the progress of this new business and continue to receive positive feedback from retailers. As evidenced by the amended executive employment agreements and the recent decision by our board of directors to defer payment of cash compensation for 2011, everyone at our company is committed to the success of our strategic objectives."  

    First Quarter 2011 compared to First Quarter 2010 Financial ResultsTotal revenues for the quarter ended March 31, 2011 were $184,000, an 11% increase, compared to $166,000 for the same period in 2010. This increase is due to the recognition of $100,000 in revenue attributable to our contract with RedHill Biopharma Ltd. for certain development services in connection with the license by RedHill of our CDT platforms for use in Ondansetron tablet formulations. Off-setting this increase is a $75,000 reduction in royalty revenue from sales of SCOLR nutritional products by Perrigo Company ("Perrigo"). The Company receives royalty payments based on Perrigo's net profits derived from the sales of products subject to the license agreement.  As previously reported, during the fourth quarter of 2010, the Company was informed by Perrigo that some retail accounts will no longer carry certain Perrigo products.  The Company expects revenues from Perrigo to decrease substantially as remaining product inventory is sold through during the first half of 2011. 

    For the quarter ended March 31, 2011, the Company's marketing and selling expenses increased 112%, or $66,000 to $125,000 for the three months ended March 31, 2011, compared to $59,000 for the same period in 2010.  

    Research and development expenses increased 90%, or $307,000, to $647,000 for the three months ended March 31, 2011, compared to $340,000 for the same period in 2010.  This increase is due primarily to advancement during the first quarter of 2011 of the "actual use" study required to be completed in advance of regulatory submission of our ibuprofen lead product, research and development work for RedHill, and formulation work related to nutritional products.

    Net loss increased 16%, or $171,000 to $1,222,000 for the three months ended March 31, 2011, compared to $1,051,000 for the same period in 2010. The increase in net loss reflects higher research and development expenses primarily associated with clinical supplies and preparation activities related to the ibuprofen actual use study. The Company has ceased substantially all clinical activities related to its lead ibuprofen product to conserve capital resources.

    SCOLR Pharma had approximately $822,000 in cash and cash equivalents as of March 31, 2011. Based on its existing cash and cash equivalents, absent additional funding, the Company will be unable to fund its operations through the second quarter of 2011.

    About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented Controlled Delivery Technology (CDT) platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit

    This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's inability to fund its operations through the second quarter of 2011, anticipated orders of its nutritional products, the effectiveness of its expense reduction efforts and projections concerning the profitability of its nutritional business.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future.  A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to reduce expenses, generate revenue and/or obtain financing necessary to continue our operations and unanticipated changes in the timing, amount or terms of orders for our nutritional products.  For example, if we are not successful in raising additional capital in the near term, we may be required to further curtail or cease our operations.  Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.SCOLR Pharma, Inc.CONDENSED UNAUDITED BALANCE SHEETS(In thousands, except par values and number of shares)March 31,2011December 31,
    2010ASSETSCurrent AssetsCash and cash equivalents$


    1,891Accounts receivable and other receivables67103Inventory323324Prepaid expenses and other assets145270Total current assets1,3572,588Property and Equipment — net of accumulated depreciation of $242 and $217, respectively303327Intangible assets — net of accumulated amortization of $382 and $354, respectively672686Restricted cash257257$


    3,858LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable$


    145Accrued liabilities319307Deferred revenue—56Fair value of warrant  45150Total current liabilities547658Deferred rent 149159Total liabilities696817Commitments and Contingencies ——Stockholders' EquityPreferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding——Common stock, authorized 100,000,000 shares, $.001 par value  49,816,073 issued and outstanding as of March 31, 2011, and December 31, 20104949Additional paid-in capital77,11577,041Accumulated deficit(75,271)(74,049)Total stockholders' equity1,8933,041$


    3,858SCOLR Pharma, Inc.CONDENSED UNAUDITED STATEMENTS OF OPERATIONS(In thousands, except per share amounts and number of shares)Three months endedMarch 31, 20112010(Restated) RevenuesLicensing fees$


    25Royalty income66141Research and development 118—Total revenues184166Operating expensesMarketing and selling12559Research and development647340General and administrative740601Total operating expenses1,5121,000Loss from operations(1,328)(834)Other income (expense)Interest income11Unrealized gain (loss) on fair value of warrant105(218)Total other income (expense)106(217)Net loss$


    (1,051)Net loss per share, basic and diluted$


    (0.02)Shares used in computing basic and diluted net loss per share49,816,07343,140,968Contacts:
    Investor Relations:
    SCOLR Pharma, Inc.


    SOURCE SCOLR Pharma, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
    2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
    3. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
    4. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
    5. SCOLR Pharma, Inc. Licenses Dietary Supplements
    6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
    7. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
    8. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
    9. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
    10. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
    11. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
    Post Your Comments:
    (Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
    (Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
    (Date:11/26/2015)... Research and Markets ( ) has ... Market by Type (Dressings, Therapy Devices, Active Wound Care), ... Facility), and Geography - Global Forecast to 2020" ... --> The purpose of this report ... the global advanced wound care market. It involves deep ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
    (Date:11/25/2015)... ... 2015 , ... Ministers, senior government and UN agencies, representatives ... of Excellence, and public R&D institutions, civil societies and other partners gathered today ... African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day ...
    (Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens ... Bruxism, and moderate facial wrinkling. While many patients are aware of the benefits of ... success Botox® delivers to those suffering with discomfort, soreness, and pain as a result ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... “While riding the ... inventor, from Bronx, N.Y. “I thought there had to be a convenient and comfortable ... PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or inclement ...
    Breaking Medicine News(10 mins):